eXoZymes Inc reported a non-revenue generating QQ1 2026 with a net loss of $2.37 million. Total operating expenses were $2.38 million, led by research and development of $1.12 million and general & administrative costs of $1.26 million. Interest expense stood at $13,716, and diluted EPS was -$0.28 on 8.46 million weighted-average shares. The quarter underscores the company’s positioning as an early-stage biotechnology platform company prioritizing platform development over near-term monetization. The absence of revenue data constrains conventional profitability and growth-rate judgments, though the implied burn rate remains a critical factor for liquidity runway.
Key Performance Indicators
Net Income
Decreasing
-2.37M
QoQ: 35.45% | YoY: -135.04%
EPS
Decreasing
-0.28
QoQ: N/A | YoY: -133.33%
Revenue Trend
Margin Analysis
Financial Highlights
Key metrics (Q1 2026, USD, unless noted):
- Revenue: N/A (no revenue disclosed in QQ1 2026 quarterly data)
- Net Income: -$2,370,247; YoY: -135.04%; QoQ: +35.45%
- EPS (diluted): -$0.28; YoY: -133.33%; QoQ: N/A
- R&D Expenses: $1,121,008
- General & Administrative Expenses: $1,255,661
- Operating Expenses: $2,376,669
- Interest Expense: $13,716
- Other: Weighted Average Shares Outstanding: 8,458,847
- EBITDA / EBITDA margin: Not disclosed
- Gross Profit / Gross Margin: Not disclosed
- Revenue growth / profit margins: Not disclosed due to missing revenue data
Income Statement
Metric
Value
YoY Change
QoQ Change
Net Income
-2.37M
-135.04%
35.45%
EPS
-0.28
-133.33%
N/A
Key Financial Ratios
Management Insights Available for Members
Get exclusive access to management commentary, earnings call quotes, and forward guidance from company leadership.